Sumitomo Heavy Industries has announced a strategic investment in Alpha Fusion Inc., a company focused on developing Astatine-based radiopharmaceuticals for Targeted Alpha Therapy (TAT). This investment aims to progress Alpha Fusion's pipeline, particularly in the mass production of Astatine-211, crucial for TAT's effectiveness in treating cancer. The technology leveraged includes particle accelerators and radio-isotope labeled compounds, which could significantly advance cancer treatment methods. Ongoing clinical trials in Japan for various cancer types are expected to enhance the prospects for TAT as a leading cancer therapy.
Sumitomo Heavy Industries, Ltd. (Tokyo:6302) has secured an order from Taichung Veterans General Hospital in Taiwan for a next-generation proton therapy system. This system will be installed at a new proton therapy center in Taichung City, with operations expected to commence in 2026. This marks the first order for SHI's next-generation technology, which features a compact design that reduces building volume by approximately 30%. The system aims to enhance cancer treatment in East Asia, enabling more precise, less invasive therapy that minimizes damage to surrounding healthy tissues.
Sumitomo Heavy Industries (SHI) has achieved a milestone in the development of its next-generation proton therapy system by successfully conducting proton beam acceleration tests on its superconducting cyclotron. The cyclotron generated a high-intensity proton beam of 1,000 nA, the highest globally for proton therapy. This innovative technology shortens the irradiation time to less than one-third of the conventional method while also reducing power consumption by 40%. SHI aims to enhance the accessibility of proton therapy for cancer patients through these advancements.